vs
MACH NATURAL RESOURCES LP（MNR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是MACH NATURAL RESOURCES LP的2.0倍（$772.1M vs $387.5M），MACH NATURAL RESOURCES LP净利率更高（18.9% vs 12.7%，领先6.1%），MACH NATURAL RESOURCES LP同比增速更快（65.0% vs 5.9%），过去两年MACH NATURAL RESOURCES LP的营收复合增速更高（27.3% vs 9.0%）
Mach Natural Resources LP是一家总部位于美国的上游能源企业，主要从事石油、天然气及液化天然气的勘探、开发与生产业务，核心运营资产分布在二叠纪盆地等美国陆上油气产区，专注于开发低成本高收益资产，为利益相关方创造可持续回报。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MNR vs RVTY — 直观对比
营收规模更大
RVTY
是对方的2.0倍
$387.5M
营收增速更快
MNR
高出59.1%
5.9%
净利率更高
MNR
高出6.1%
12.7%
两年增速更快
MNR
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $387.5M | $772.1M |
| 净利润 | $73.1M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 26.1% | 14.5% |
| 净利率 | 18.9% | 12.7% |
| 营收同比 | 65.0% | 5.9% |
| 净利润同比 | 100.2% | 3.9% |
| 每股收益（稀释后） | $0.47 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MNRRVTY
| Q4 25 | $387.5M | $772.1M | ||
| Q3 25 | $272.6M | $698.9M | ||
| Q2 25 | $288.5M | $720.3M | ||
| Q1 25 | $226.8M | $664.8M | ||
| Q4 24 | $234.9M | $729.4M | ||
| Q3 24 | $255.5M | $684.0M | ||
| Q2 24 | $240.0M | $691.7M | ||
| Q1 24 | $239.2M | $649.9M |
净利润MNRRVTY
| Q4 25 | $73.1M | $98.4M | ||
| Q3 25 | $-35.7M | $46.7M | ||
| Q2 25 | $89.7M | $53.9M | ||
| Q1 25 | $15.9M | $42.2M | ||
| Q4 24 | $36.5M | $94.6M | ||
| Q3 24 | $67.4M | $94.4M | ||
| Q2 24 | $39.5M | $55.4M | ||
| Q1 24 | $41.7M | $26.0M |
毛利率MNRRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率MNRRVTY
| Q4 25 | 26.1% | 14.5% | ||
| Q3 25 | -7.0% | 11.7% | ||
| Q2 25 | 38.6% | 12.6% | ||
| Q1 25 | 22.8% | 10.9% | ||
| Q4 24 | 24.9% | 16.3% | ||
| Q3 24 | 37.1% | 14.3% | ||
| Q2 24 | 29.4% | 12.4% | ||
| Q1 24 | 28.1% | 6.8% |
净利率MNRRVTY
| Q4 25 | 18.9% | 12.7% | ||
| Q3 25 | -13.1% | 6.7% | ||
| Q2 25 | 31.1% | 7.5% | ||
| Q1 25 | 7.0% | 6.4% | ||
| Q4 24 | 15.5% | 13.0% | ||
| Q3 24 | 26.4% | 13.8% | ||
| Q2 24 | 16.5% | 8.0% | ||
| Q1 24 | 17.4% | 4.0% |
每股收益（稀释后）MNRRVTY
| Q4 25 | $0.47 | $0.86 | ||
| Q3 25 | $-0.28 | $0.40 | ||
| Q2 25 | $0.76 | $0.46 | ||
| Q1 25 | $0.14 | $0.35 | ||
| Q4 24 | $0.34 | $0.77 | ||
| Q3 24 | $0.70 | $0.77 | ||
| Q2 24 | $0.42 | $0.45 | ||
| Q1 24 | $0.44 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $42.6M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $3.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MNRRVTY
| Q4 25 | $42.6M | $919.9M | ||
| Q3 25 | $53.6M | $931.4M | ||
| Q2 25 | $13.8M | $991.8M | ||
| Q1 25 | $7.8M | $1.1B | ||
| Q4 24 | $105.8M | $1.2B | ||
| Q3 24 | $184.5M | $1.2B | ||
| Q2 24 | $144.6M | $2.0B | ||
| Q1 24 | $151.3M | $1.7B |
股东权益MNRRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | — | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产MNRRVTY
| Q4 25 | $3.8B | $12.2B | ||
| Q3 25 | $3.8B | $12.1B | ||
| Q2 25 | $2.3B | $12.4B | ||
| Q1 25 | $2.2B | $12.4B | ||
| Q4 24 | $2.3B | $12.4B | ||
| Q3 24 | $2.3B | $12.8B | ||
| Q2 24 | $2.2B | $13.4B | ||
| Q1 24 | $2.3B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $128.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.76× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流MNRRVTY
| Q4 25 | $128.7M | $182.0M | ||
| Q3 25 | $105.5M | $138.5M | ||
| Q2 25 | $130.1M | $134.3M | ||
| Q1 25 | $142.5M | $128.2M | ||
| Q4 24 | $133.7M | $174.2M | ||
| Q3 24 | $110.8M | $147.9M | ||
| Q2 24 | $116.8M | $158.6M | ||
| Q1 24 | $144.0M | $147.6M |
自由现金流MNRRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率MNRRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度MNRRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率MNRRVTY
| Q4 25 | 1.76× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 1.45× | 2.49× | ||
| Q1 25 | 8.97× | 3.03× | ||
| Q4 24 | 3.66× | 1.84× | ||
| Q3 24 | 1.64× | 1.57× | ||
| Q2 24 | 2.96× | 2.87× | ||
| Q1 24 | 3.45× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MNR
| Oil Gas And Natural Gas Liquids Net | $331.0M | 85% |
| Natural Gas Liquids Reserves | $44.8M | 12% |
| Natural Gas Midstream | $8.6M | 2% |
| Products | $6.3M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
